HomeCompanies › DRTS

Alpha Tau Medical

Most recent annual filing: 2025-12-31

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. Head & Neck Cancer +2026Head & Neck Cancer +, 2026, routine
  2. Alpha DaRT SCC pivotal topline3Q 2026Alpha DaRT SCC pivotal topline, 3Q 2026, thesis-defining
  3. IMPACT pancreas pilot corporate updateLate 2026 / early 2027IMPACT pancreas pilot corporate update, Late 2026 / early 2027, routine
  4. Pancreas IMPACT corporate updateearly 2027Pancreas IMPACT corporate update, early 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

Alpha DaRT

Alpha Diffusing Alpha-emitters Radiation Therapy — intratumoral Radium-224-embedded radioactive source technology delivering controlled release of alpha-emitting atoms throughout solid tumors; focus areas include squamous cell carcinoma, glioblastoma multiforme, pancreatic cancer, head and neck cancer, and other solid tumors

Biotech Distilled coverage (17)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.